{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:03:53Z","timestamp":1792879433830,"version":"4.5.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970298"],"award-info":[{"award-number":["81970298"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100355"],"award-info":[{"award-number":["82100355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Special Fund of Zhongshan Hospital Fudan University","award":["2020ZSLC57"],"award-info":[{"award-number":["2020ZSLC57"]}]},{"DOI":"10.13039\/501100015359","name":"2021 clinical research navigation project of Shanghai Medical College of Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai sailing program","award":["21YF1406000"],"award-info":[{"award-number":["21YF1406000"]}]},{"name":"Shanghai Municipal Key Clinicial Specialty","award":["shslczdzk06201"],"award-info":[{"award-number":["shslczdzk06201"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Fetuin-A, a liver-derived heterodimeric plasma glycoprotein, exhibits abnormal elevation in non-alcoholic fatty liver disease (NAFLD). Plasma fetuin-A levels correlate closely with both morbidity and mortality associated with cardiovascular diseases. However, the precise influence of fetuin-A on NAFLD-related platelet activation and thrombosis remains to be elucidated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Fetuin-A directly amplified agonist-induced platelet aggregation, dense granule adenosine triphosphate release, P-selectin exposure, integrin \u03b1IIb\u03b23 activation, spreading, and clot retraction. Mechanistically, fetuin-A bound to platelet Toll-like receptor-4 (TLR-4), activating TLR-4\/MyD88, SFK\/PI3\u2005K\/AKT, cGMP\/PKG, and mitogen-activated protein kinase signalling pathways to enhance platelet activation. TLR-4 specific antagonist TAK-242 and TLR-4-deficient mice confirmed the TLR-4 dependence of these effects. Oral administration of firsocostat, rosuvastatin, or pioglitazone demonstrated efficacy in alleviating thrombosis formation in NAFLD mice by reducing fetuin-A levels and attenuating platelet hyperreactivity. Notably, the fetuin-A-inhibiting antibody potently suppressed platelet activation and inhibited thrombosis formation in NAFLD mice. Administration of this antibody attenuated thromboembolism and microvascular thrombosis in NAFLD mice, thereby safeguarding the lung, heart, and brain from exacerbated tissue infarcts. Finally, a positive correlation between plasma fetuin-A concentration and platelet aggregation was observed in NAFLD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Fetuin-A emerges as a positive regulator of platelet hyperreactivity in NAFLD. Acting via TLR-4-dependent signalling pathways, plasma fetuin-A directly amplifies platelet activation and promotes in vivo thrombosis. Firsocostat, rosuvastatin, and pioglitazone abrogate these enhancing effects by reducing fetuin-A levels. The fetuin-A-inhibiting antibody presents potential therapeutic advantages to prevent thrombotic complications in NAFLD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cvr\/cvaf096","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T23:09:32Z","timestamp":1751065772000},"page":"1091-1107","source":"Crossref","is-referenced-by-count":13,"title":["Fetuin-A increases thrombosis risk in non-alcoholic fatty liver disease by binding to TLR-4 on platelets"],"prefix":"10.1093","volume":"121","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Zhongshan Hospital, Fudan University , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luning","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"NHC Key Laboratory of Ischaemic Heart Diseases , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"National Clinical Research Center for Interventional Medicine , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"NHC Key Laboratory of Ischaemic Heart Diseases , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"National Clinical Research Center for Interventional Medicine , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-7332","authenticated-orcid":false,"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University , 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"NHC Key Laboratory of Ischaemic Heart Diseases , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"National Clinical Research Center for Interventional Medicine , Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032 ,","place":["China"]},{"name":"Institutes of Biomedical Sciences, Fudan University , 131 Dongan Road, Shanghai 200032 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"2025070809314958900_cvaf096-B1","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025070809314958900_cvaf096-B2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"2025070809314958900_cvaf096-B3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jhep.2017.12.012","article-title":"Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study","volume":"68","author":"Lee","year":"2018","journal-title":"J Hepatol"},{"key":"2025070809314958900_cvaf096-B4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"2025070809314958900_cvaf096-B5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"2025070809314958900_cvaf096-B6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2025070809314958900_cvaf096-B7","doi-asserted-by":"crossref","first-page":"106766","DOI":"10.1016\/j.prostaglandins.2023.106766","article-title":"The role of platelets in non-alcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"169","author":"Malladi","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2025070809314958900_cvaf096-B8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s10787-021-00837-4","article-title":"Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD","volume":"29","author":"Sardana","year":"2021","journal-title":"Inflammopharmacology"},{"key":"2025070809314958900_cvaf096-B9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4093\/dmj.2011.35.5.523","article-title":"Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus","volume":"35","author":"Gunduz","year":"2011","journal-title":"Diabetes Metab J"},{"key":"2025070809314958900_cvaf096-B10","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.3390\/ijms22126627","article-title":"The evolving role of Fetuin-A in nonalcoholic fatty liver disease: an overview from liver to the heart","volume":"22","author":"Dogru","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025070809314958900_cvaf096-B11","doi-asserted-by":"crossref","first-page":"c233","DOI":"10.1159\/000120209","article-title":"Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease","volume":"108","author":"Caglar","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"2025070809314958900_cvaf096-B12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/1354750X.2012.762806","article-title":"Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes","volume":"18","author":"Zhao","year":"2013","journal-title":"Biomarkers"},{"key":"2025070809314958900_cvaf096-B13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2265.2006.02716.x","article-title":"Association of serum fetuin-A with carotid arterial stiffness","volume":"66","author":"Mori","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025070809314958900_cvaf096-B14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2265.2012.04460.x","article-title":"Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease","volume":"78","author":"Dogru","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025070809314958900_cvaf096-B15","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/CIRCULATIONAHA.108.814418","article-title":"Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke","volume":"118","author":"Weikert","year":"2008","journal-title":"Circulation"},{"key":"2025070809314958900_cvaf096-B16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.atherosclerosis.2016.01.037","article-title":"Facilitatory effects of fetuin-A on atherosclerosis","volume":"246","author":"Naito","year":"2016","journal-title":"Atherosclerosis"},{"key":"2025070809314958900_cvaf096-B17","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1210\/jc.2012-2414","article-title":"Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose","volume":"97","author":"Ou","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2025070809314958900_cvaf096-B18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/EJE-11-0864","article-title":"Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies","volume":"166","author":"Haukeland","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2025070809314958900_cvaf096-B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.numecd.2017.09.008","article-title":"Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease","volume":"28","author":"Pampanini","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025070809314958900_cvaf096-B20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.advms.2013.08.003","article-title":"Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease","volume":"59","author":"Lebensztejn","year":"2014","journal-title":"Adv Med Sci"},{"key":"2025070809314958900_cvaf096-B21","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1161\/CIRCRESAHA.122.321787","article-title":"IL-37 Attenuates platelet activation and thrombosis through IL-1R8 pathway","volume":"132","author":"Chen","year":"2023","journal-title":"Circ Res"},{"key":"2025070809314958900_cvaf096-B22","first-page":"162","article-title":"New concepts and mechanisms of platelet activation signaling","volume":"32","author":"Estevez","year":"2017","journal-title":"Physiology (Bethesda)"},{"key":"2025070809314958900_cvaf096-B23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nature12613","article-title":"A directional switch of integrin signalling and a new anti-thrombotic strategy","volume":"503","author":"Shen","year":"2013","journal-title":"Nature"},{"key":"2025070809314958900_cvaf096-B24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1073\/pnas.1118579109","article-title":"Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking toll-like receptors (TLRs) to serine\/threonine kinases PI3K\/Akt","volume":"109","author":"Troutman","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025070809314958900_cvaf096-B25","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/s44318-024-00056-x","article-title":"A mosquito salivary protein-driven influx of myeloid cells facilitates flavivirus transmission","volume":"43","author":"Wang","year":"2024","journal-title":"EMBO J"},{"key":"2025070809314958900_cvaf096-B26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/bip.22095","article-title":"Biophysical characterization of polymyxin B interaction with LPS aggregates and membrane model systems","volume":"98","author":"Domingues","year":"2012","journal-title":"Biopolymers"},{"key":"2025070809314958900_cvaf096-B27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2796.2003.01296.x","article-title":"Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function","volume":"255","author":"M\u00fcller","year":"2004","journal-title":"J Intern Med"},{"key":"2025070809314958900_cvaf096-B28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13000-015-0348-3","article-title":"HMGB1: a novel protein that induced platelets active and aggregation via toll-like receptor-4, NF-\u03baB and cGMP dependent mechanisms","volume":"10","author":"Yang","year":"2015","journal-title":"Diagn Pathol"},{"key":"2025070809314958900_cvaf096-B29","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1039\/D2FO03958C","article-title":"Sulforaphane attenuates glycoprotein VI-mediated platelet mitochondrial dysfunction through up-regulating the cAMP\/PKA signaling pathway in vitro and in vivo","volume":"14","author":"Zhou","year":"2023","journal-title":"Food Funct"},{"key":"2025070809314958900_cvaf096-B30","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/ijms24021010","article-title":"Toll-like receptors and thrombopoiesis","volume":"24","author":"Tang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025070809314958900_cvaf096-B31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"key":"2025070809314958900_cvaf096-B32","doi-asserted-by":"crossref","first-page":"eabg8117","DOI":"10.1126\/scitranslmed.abg8117","article-title":"Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025070809314958900_cvaf096-B33","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/eurheartj\/ehac109","article-title":"Circadian nuclear receptor Rev-erb\u03b1 is expressed by platelets and potentiates platelet activation and thrombus formation","volume":"43","author":"Shi","year":"2022","journal-title":"Eur Heart J"},{"key":"2025070809314958900_cvaf096-B34","doi-asserted-by":"crossref","first-page":"113184","DOI":"10.1016\/j.biopha.2022.113184","article-title":"Stachydrine exhibits a novel antiplatelet property and ameliorates platelet-mediated thrombo-inflammation","volume":"152","author":"Sun","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025070809314958900_cvaf096-B35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-020-14958-x","article-title":"Red blood cell-derived semaphorin 7A promotes thrombo-inflammation in myocardial ischemia-reperfusion injury through platelet GPIb","volume":"11","author":"K\u00f6hler","year":"2020","journal-title":"Nat Commun"},{"key":"2025070809314958900_cvaf096-B36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/00031305.1977.10479195","article-title":"Desk calculation of probabilities for the distribution of the sample correlation coefficient","volume":"31","author":"Guenther","year":"1977","journal-title":"Am Stat"},{"key":"2025070809314958900_cvaf096-B37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.22158\/wjssr.v3n1p37","article-title":"Sample size guideline for correlation analysis","volume":"3","author":"Bujang","year":"2016","journal-title":"World J Soc Sci Res"},{"key":"2025070809314958900_cvaf096-B38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0303-7207(00)00237-9","article-title":"Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor","volume":"164","author":"Mathews","year":"2000","journal-title":"Mol Cell Endocrinol"},{"key":"2025070809314958900_cvaf096-B39","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.2337\/diabetes.51.8.2450","article-title":"Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene","volume":"51","author":"Mathews","year":"2002","journal-title":"Diabetes"},{"key":"2025070809314958900_cvaf096-B40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1042\/BJ20100330","article-title":"NF-kappaB mediates lipid-induced fetuin-A expression in hepatocytes that impairs adipocyte function effecting insulin resistance","volume":"429","author":"Dasgupta","year":"2010","journal-title":"Biochem J"},{"key":"2025070809314958900_cvaf096-B41","doi-asserted-by":"crossref","first-page":"e1765","DOI":"10.1371\/journal.pone.0001765","article-title":"Fetuin-A induces cytokine expression and suppresses adiponectin production","volume":"3","author":"Hennige","year":"2008","journal-title":"PLoS One"},{"key":"2025070809314958900_cvaf096-B42","doi-asserted-by":"crossref","first-page":"19991","DOI":"10.1074\/jbc.M112234200","article-title":"Alpha 2-HS glycoprotein\/fetuin, a transforming growth factor-beta\/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling","volume":"277","author":"Szweras","year":"2002","journal-title":"J Biol Chem"},{"key":"2025070809314958900_cvaf096-B43","doi-asserted-by":"crossref","first-page":"17092","DOI":"10.1074\/jbc.M109.007013","article-title":"Mineralization by inhibitor exclusion: the calcification of collagen with fetuin","volume":"284","author":"Price","year":"2009","journal-title":"J Biol Chem"},{"key":"2025070809314958900_cvaf096-B44","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0092-8674(89)90098-6","article-title":"Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity","volume":"58","author":"Auberger","year":"1989","journal-title":"Cell"},{"key":"2025070809314958900_cvaf096-B45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.300.2.182","article-title":"Fetuin-A and incident diabetes mellitus in older persons","volume":"300","author":"Ix","year":"2008","journal-title":"JAMA"},{"key":"2025070809314958900_cvaf096-B46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","article-title":"Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease","volume":"118","author":"Puchades","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"2025070809314958900_cvaf096-B47","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4158\/EP14421.RA","article-title":"Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome","volume":"20","author":"Mukhopadhyay","year":"2014","journal-title":"Endocr Pract"},{"key":"2025070809314958900_cvaf096-B48","doi-asserted-by":"crossref","first-page":"945287","DOI":"10.3389\/fcell.2022.945287","article-title":"The structure, biosynthesis, and biological roles of fetuin-A: a review","volume":"10","author":"Chekol Abebe","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2025070809314958900_cvaf096-B49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/B978-0-12-394317-0.00010-8","article-title":"Fetuin-A and the cardiovascular system","volume":"56","author":"Mori","year":"2012","journal-title":"Adv Clin Chem"},{"key":"2025070809314958900_cvaf096-B50","doi-asserted-by":"crossref","first-page":"e0228503","DOI":"10.1371\/journal.pone.0228503","article-title":"Lumenal calcification and microvasculopathy in fetuin-A-deficient mice lead to multiple organ morbidity","volume":"15","author":"Herrmann","year":"2020","journal-title":"PLoS One"},{"key":"2025070809314958900_cvaf096-B51","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/CIRCGENETICS.109.870410","article-title":"Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study","volume":"2","author":"Fisher","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"2025070809314958900_cvaf096-B52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2016.03.029","article-title":"Fetuin-A, glycemic status, and risk of cardiovascular disease: the multi-ethnic study of atherosclerosis","volume":"248","author":"Aroner","year":"2016","journal-title":"Atherosclerosis"},{"key":"2025070809314958900_cvaf096-B53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/diseases6010017","article-title":"Do nonalcoholic fatty liver disease and Fetuin-A play different roles in symptomatic coronary artery disease and peripheral arterial disease?","volume":"6","author":"Nascimbeni","year":"2018","journal-title":"Diseases"},{"key":"2025070809314958900_cvaf096-B54","doi-asserted-by":"crossref","first-page":"e0123685","DOI":"10.1371\/journal.pone.0123685","article-title":"TLR4\/NF-\u03baB signaling contributes to chronic unpredictable mild stress-induced atherosclerosis in ApoE-\/- mice","volume":"10","author":"Tang","year":"2015","journal-title":"PLoS One"},{"key":"2025070809314958900_cvaf096-B55","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm.2851","article-title":"Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance","volume":"18","author":"Pal","year":"2012","journal-title":"Nat Med"},{"key":"2025070809314958900_cvaf096-B56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bcp.2019.05.011","article-title":"Hepatic upregulation of fetuin-A mediates Acetaminophen-induced liver injury through activation of TLR4 in mice","volume":"166","author":"Lee","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"2025070809314958900_cvaf096-B57","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2005-03-0916","article-title":"Platelets express functional toll-like receptor-4","volume":"106","author":"Andonegui","year":"2005","journal-title":"Blood"},{"key":"2025070809314958900_cvaf096-B58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2019.12.017","article-title":"Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity","volume":"294","author":"Jerez-Dolz","year":"2020","journal-title":"Atherosclerosis"},{"key":"2025070809314958900_cvaf096-B59","doi-asserted-by":"crossref","first-page":"7997","DOI":"10.4049\/jimmunol.0802884","article-title":"Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4\/MyD88 and the cGMP-dependent protein kinase pathway","volume":"182","author":"Zhang","year":"2009","journal-title":"J Immunol"},{"key":"2025070809314958900_cvaf096-B60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"2025070809314958900_cvaf096-B61","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic De Novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025070809314958900_cvaf096-B62","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 Reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"2025070809314958900_cvaf096-B63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes Mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"2025070809314958900_cvaf096-B64","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"2025070809314958900_cvaf096-B65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map","volume":"8","author":"Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025070809314958900_cvaf096-B66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.dsx.2014.09.009","article-title":"Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial","volume":"9","author":"Esteghamati","year":"2015","journal-title":"Diabetes Metab Syndr"},{"key":"2025070809314958900_cvaf096-B67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"key":"2025070809314958900_cvaf096-B68","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cardiores.2004.11.027","article-title":"The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation","volume":"65","author":"Li","year":"2005","journal-title":"Cardiovasc Res"},{"key":"2025070809314958900_cvaf096-B69","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"key":"2025070809314958900_cvaf096-B70","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1093\/eurheartj\/ehac448","article-title":"Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases","volume":"43","author":"Zhou","year":"2022","journal-title":"Eur Heart J"},{"key":"2025070809314958900_cvaf096-B71","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"2025070809314958900_cvaf096-B72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00223-012-9690-6","article-title":"The role of fetuin-A in physiological and pathological mineralization","volume":"93","author":"Brylka","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"2025070809314958900_cvaf096-B73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/bs.acc.2018.12.003","article-title":"Clinical implications of fetuin-A","volume":"89","author":"Jirak","year":"2019","journal-title":"Adv Clin Chem"},{"key":"2025070809314958900_cvaf096-B74","doi-asserted-by":"crossref","first-page":"e0136822","DOI":"10.1371\/journal.pone.0136822","article-title":"Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease","volume":"10","author":"Pacana","year":"2015","journal-title":"PLoS One"},{"key":"2025070809314958900_cvaf096-B75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2021.02.124","article-title":"Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD","volume":"555","author":"Li","year":"2021","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvaf096\/63531680\/cvaf096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/121\/7\/1091\/63531680\/cvaf096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/121\/7\/1091\/63531680\/cvaf096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T13:32:02Z","timestamp":1751981522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/121\/7\/1091\/8169754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":75,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,6,20]]},"published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvaf096","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]}}}